PDF(Pubmed)
Abstract：
BACKGROUND: Only a small number of studies have reported the use of progesterone vaginal gel in combination with dydrogesterone as part of the antagonist protocol for fresh embryo transfer. Therefore, this study aimed to compare the effects of two types of luteal support on pregnancy outcomes following the antagonist protocol for fresh embryo transfer.
METHODS: We performed a retrospective analysis of clinical data from infertile patients who underwent fresh embryo transfer via the antagonist protocol (2785 cycles) between February and July 2019 and between February and July 2021 at the Peking University Third Hospital Reproductive Medicine Centre. According to the luteal support received, the cycle groups were divided into the progesterone vaginal gel group (single medication or VP group; 1170 cycles) and the progesterone vaginal gel plus dydrogesterone group (combination medication or DYD + VP group; 1615 cycles). After propensity score matching, the clinical pregnancy, ongoing pregnancy, early miscarriage, and ectopic pregnancy rates were compared between the two groups.
RESULTS: In total, 1057 pairs of cycles were successfully matched via propensity scores. The clinical and ongoing pregnancy rates in the combination medication group were significantly higher than those in the single medication group (P < 0.05), whereas no significant differences were noted in the early miscarriage and ectopic pregnancy rates between the two groups (both P > 0.05).
CONCLUSIONS: Combined luteal support after the antagonist protocol is preferred for patients undergoing fresh cycle embryo transfer.
METHODS: We performed a retrospective analysis of clinical data from infertile patients who underwent fresh embryo transfer via the antagonist protocol (2785 cycles) between February and July 2019 and between February and July 2021 at the Peking University Third Hospital Reproductive Medicine Centre. According to the luteal support received, the cycle groups were divided into the progesterone vaginal gel group (single medication or VP group; 1170 cycles) and the progesterone vaginal gel plus dydrogesterone group (combination medication or DYD + VP group; 1615 cycles). After propensity score matching, the clinical pregnancy, ongoing pregnancy, early miscarriage, and ectopic pregnancy rates were compared between the two groups.
RESULTS: In total, 1057 pairs of cycles were successfully matched via propensity scores. The clinical and ongoing pregnancy rates in the combination medication group were significantly higher than those in the single medication group (P < 0.05), whereas no significant differences were noted in the early miscarriage and ectopic pregnancy rates between the two groups (both P > 0.05).
CONCLUSIONS: Combined luteal support after the antagonist protocol is preferred for patients undergoing fresh cycle embryo transfer.
摘要：
背景：只有少数研究报道了孕酮阴道凝胶联合地屈孕酮作为新鲜胚胎移植拮抗剂方案的一部分。因此,本研究旨在比较两种黄体支持对新鲜胚胎移植拮抗剂方案后妊娠结局的影响.
方法：我们对2019年2月至7月和2021年2月至7月在北京大学第三医院生殖医学中心接受拮抗剂方案新鲜胚胎移植（2785个周期）的不孕患者的临床数据进行了回顾性分析。根据获得的黄体支持，周期组分为黄体酮阴道凝胶组(单一用药或VP组;1170个周期)和黄体酮阴道凝胶加地屈孕酮组(联合用药或DYD+VP组;1615个周期)。在倾向得分匹配后，临床妊娠,正在怀孕,早期流产,比较两组的异位妊娠率。
结果：总计，通过倾向评分成功匹配了1057对周期。联合用药组的临床妊娠率及持续妊娠率均明显高于单一用药组(P<0.05),而两组早期流产率和异位妊娠率无显著差异(均P>0.05)。
结论：对于接受新鲜周期胚胎移植的患者，拮抗剂方案后的联合黄体支持是优选的。
方法：我们对2019年2月至7月和2021年2月至7月在北京大学第三医院生殖医学中心接受拮抗剂方案新鲜胚胎移植（2785个周期）的不孕患者的临床数据进行了回顾性分析。根据获得的黄体支持，周期组分为黄体酮阴道凝胶组(单一用药或VP组;1170个周期)和黄体酮阴道凝胶加地屈孕酮组(联合用药或DYD+VP组;1615个周期)。在倾向得分匹配后，临床妊娠,正在怀孕,早期流产,比较两组的异位妊娠率。
结果：总计，通过倾向评分成功匹配了1057对周期。联合用药组的临床妊娠率及持续妊娠率均明显高于单一用药组(P<0.05),而两组早期流产率和异位妊娠率无显著差异(均P>0.05)。
结论：对于接受新鲜周期胚胎移植的患者，拮抗剂方案后的联合黄体支持是优选的。
